Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma
Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with...
Saved in:
| Published in | Cancers Vol. 15; no. 14; p. 3630 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI AG
15.07.2023
MDPI |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2072-6694 2072-6694 |
| DOI | 10.3390/cancers15143630 |
Cover
| Abstract | Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with recurrence. In this study, we investigated how frequently CTCs were identified prior to radiologically detected recurrence. Stage III patients (n = 325) had imaging at baseline and q 3 months. Baseline and q 6–12 months blood draws (7.5 mL) were performed to identify CTCs up to 3.5 years from diagnosis. CTC assessment was performed using the immunomagnetic capture of CD146-positive cells and anti-MEL-PE. The presence of one or more CTCs was considered positive. We analyzed the cohort of patients with relapse confirmed by radiologic imaging. CTC collection dates were assessed to determine the lead time for CTC detection. CTC-negative patients were significantly less likely to relapse compared to patients positive for CTCs (p-value < 0.001). Within the 325-patient cohort, 143 patients (44%) had recurrence, with a median follow-up of 52 months from diagnosis. The cohort (n = 143) with positive imaging and CTC results revealed 76% of patients (108/143) had CTC+ results before the radiological identification of relapse. The median time between positive CTC and positive imaging was 9 months. CTCs were positive in >75% of patients prior to relapse at a median of 9 months before radiologic detection. |
|---|---|
| AbstractList | Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with recurrence. In this study, we investigated how frequently CTCs were identified prior to radiologically detected recurrence. Stage III patients (
= 325) had imaging at baseline and q 3 months. Baseline and q 6-12 months blood draws (7.5 mL) were performed to identify CTCs up to 3.5 years from diagnosis. CTC assessment was performed using the immunomagnetic capture of CD146-positive cells and anti-MEL-PE. The presence of one or more CTCs was considered positive. We analyzed the cohort of patients with relapse confirmed by radiologic imaging. CTC collection dates were assessed to determine the lead time for CTC detection. CTC-negative patients were significantly less likely to relapse compared to patients positive for CTCs (
-value < 0.001). Within the 325-patient cohort, 143 patients (44%) had recurrence, with a median follow-up of 52 months from diagnosis. The cohort (
= 143) with positive imaging and CTC results revealed 76% of patients (108/143) had CTC+ results before the radiological identification of relapse. The median time between positive CTC and positive imaging was 9 months. CTCs were positive in >75% of patients prior to relapse at a median of 9 months before radiologic detection. In this study, we investigated how frequently and how early circulating tumor cells (CTCs) were identified prior to the surveillance imaging detection of melanoma progression. This paper reports the results from 325 stage III melanoma patients from a prospective, IRB-approved study at our institution. These patients had blood drawn at baseline and then every 6–12 months to identify CTCs up to 3.5 years from diagnosis. Imaging (CT, PET/CT, MRI, and/or ultrasound) was conducted at baseline and then every 3 months as standard follow-up. We found that CTCs were detected in 76% of stage III melanoma patients who eventually had radiologically detected disease recurrence/metastasis and were identified at a median time of 9 months before imaging confirmation of disease progression. We believe that this finding is important as it provides the basis for future studies using CTCs to risk stratifying melanoma patients. Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with recurrence. In this study, we investigated how frequently CTCs were identified prior to radiologically detected recurrence. Stage III patients (n = 325) had imaging at baseline and q 3 months. Baseline and q 6–12 months blood draws (7.5 mL) were performed to identify CTCs up to 3.5 years from diagnosis. CTC assessment was performed using the immunomagnetic capture of CD146-positive cells and anti-MEL-PE. The presence of one or more CTCs was considered positive. We analyzed the cohort of patients with relapse confirmed by radiologic imaging. CTC collection dates were assessed to determine the lead time for CTC detection. CTC-negative patients were significantly less likely to relapse compared to patients positive for CTCs (p-value < 0.001). Within the 325-patient cohort, 143 patients (44%) had recurrence, with a median follow-up of 52 months from diagnosis. The cohort (n = 143) with positive imaging and CTC results revealed 76% of patients (108/143) had CTC+ results before the radiological identification of relapse. The median time between positive CTC and positive imaging was 9 months. CTCs were positive in >75% of patients prior to relapse at a median of 9 months before radiologic detection. Simple SummaryIn this study, we investigated how frequently and how early circulating tumor cells (CTCs) were identified prior to the surveillance imaging detection of melanoma progression. This paper reports the results from 325 stage III melanoma patients from a prospective, IRB-approved study at our institution. These patients had blood drawn at baseline and then every 6–12 months to identify CTCs up to 3.5 years from diagnosis. Imaging (CT, PET/CT, MRI, and/or ultrasound) was conducted at baseline and then every 3 months as standard follow-up. We found that CTCs were detected in 76% of stage III melanoma patients who eventually had radiologically detected disease recurrence/metastasis and were identified at a median time of 9 months before imaging confirmation of disease progression. We believe that this finding is important as it provides the basis for future studies using CTCs to risk stratifying melanoma patients.AbstractStage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with recurrence. In this study, we investigated how frequently CTCs were identified prior to radiologically detected recurrence. Stage III patients (n = 325) had imaging at baseline and q 3 months. Baseline and q 6–12 months blood draws (7.5 mL) were performed to identify CTCs up to 3.5 years from diagnosis. CTC assessment was performed using the immunomagnetic capture of CD146-positive cells and anti-MEL-PE. The presence of one or more CTCs was considered positive. We analyzed the cohort of patients with relapse confirmed by radiologic imaging. CTC collection dates were assessed to determine the lead time for CTC detection. CTC-negative patients were significantly less likely to relapse compared to patients positive for CTCs (p-value < 0.001). Within the 325-patient cohort, 143 patients (44%) had recurrence, with a median follow-up of 52 months from diagnosis. The cohort (n = 143) with positive imaging and CTC results revealed 76% of patients (108/143) had CTC+ results before the radiological identification of relapse. The median time between positive CTC and positive imaging was 9 months. CTCs were positive in >75% of patients prior to relapse at a median of 9 months before radiologic detection. Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with recurrence. In this study, we investigated how frequently CTCs were identified prior to radiologically detected recurrence. Stage III patients (n = 325) had imaging at baseline and q 3 months. Baseline and q 6-12 months blood draws (7.5 mL) were performed to identify CTCs up to 3.5 years from diagnosis. CTC assessment was performed using the immunomagnetic capture of CD146-positive cells and anti-MEL-PE. The presence of one or more CTCs was considered positive. We analyzed the cohort of patients with relapse confirmed by radiologic imaging. CTC collection dates were assessed to determine the lead time for CTC detection. CTC-negative patients were significantly less likely to relapse compared to patients positive for CTCs (p-value < 0.001). Within the 325-patient cohort, 143 patients (44%) had recurrence, with a median follow-up of 52 months from diagnosis. The cohort (n = 143) with positive imaging and CTC results revealed 76% of patients (108/143) had CTC+ results before the radiological identification of relapse. The median time between positive CTC and positive imaging was 9 months. CTCs were positive in >75% of patients prior to relapse at a median of 9 months before radiologic detection.Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with recurrence. In this study, we investigated how frequently CTCs were identified prior to radiologically detected recurrence. Stage III patients (n = 325) had imaging at baseline and q 3 months. Baseline and q 6-12 months blood draws (7.5 mL) were performed to identify CTCs up to 3.5 years from diagnosis. CTC assessment was performed using the immunomagnetic capture of CD146-positive cells and anti-MEL-PE. The presence of one or more CTCs was considered positive. We analyzed the cohort of patients with relapse confirmed by radiologic imaging. CTC collection dates were assessed to determine the lead time for CTC detection. CTC-negative patients were significantly less likely to relapse compared to patients positive for CTCs (p-value < 0.001). Within the 325-patient cohort, 143 patients (44%) had recurrence, with a median follow-up of 52 months from diagnosis. The cohort (n = 143) with positive imaging and CTC results revealed 76% of patients (108/143) had CTC+ results before the radiological identification of relapse. The median time between positive CTC and positive imaging was 9 months. CTCs were positive in >75% of patients prior to relapse at a median of 9 months before radiologic detection. In this study, we investigated how frequently and how early circulating tumor cells (CTCs) were identified prior to the surveillance imaging detection of melanoma progression. This paper reports the results from 325 stage III melanoma patients from a prospective, IRB-approved study at our institution. These patients had blood drawn at baseline and then every 6-12 months to identify CTCs up to 3.5 years from diagnosis. Imaging (CT, PET/CT, MRI, and/or ultrasound) was conducted at baseline and then every 3 months as standard follow-up. We found that CTCs were detected in 76% of stage III melanoma patients who eventually had radiologically detected disease recurrence/metastasis and were identified at a median time of 9 months before imaging confirmation of disease progression. We believe that this finding is important as it provides the basis for future studies using CTCs to risk stratifying melanoma patients. Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients is important for clinical decision making. We demonstrated previously that ≥1 circulating tumor cells (CTCs) at baseline was associated with recurrence. In this study, we investigated how frequently CTCs were identified prior to radiologically detected recurrence. Stage III patients (n = 325) had imaging at baseline and q 3 months. Baseline and q 6–12 months blood draws (7.5 mL) were performed to identify CTCs up to 3.5 years from diagnosis. CTC assessment was performed using the immunomagnetic capture of CD146-positive cells and anti-MEL-PE. The presence of one or more CTCs was considered positive. We analyzed the cohort of patients with relapse confirmed by radiologic imaging. CTC collection dates were assessed to determine the lead time for CTC detection. CTC-negative patients were significantly less likely to relapse compared to patients positive for CTCs (p-value < 0.001). Within the 325-patient cohort, 143 patients (44%) had recurrence, with a median follow-up of 52 months from diagnosis. The cohort (n = 143) with positive imaging and CTC results revealed 76% of patients (108/143) had CTC+ results before the radiological identification of relapse. The median time between positive CTC and positive imaging was 9 months. CTCs were positive in >75% of patients prior to relapse at a median of 9 months before radiologic detection. |
| Audience | Academic |
| Author | Addanki, Sridevi Ross, Merrick I. Gershenwald, Jeffrey E. Wargo, Jennifer A. Chiang, Yi-Ju Lucci, Anthony Patel, Sapna P. Upshaw, Joshua R. Manchem, Mayank Sarli, Vanessa N. Meas, Salyna |
| AuthorAffiliation | 1 Departments of Breast Surgical Oncology and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; saddanki@mdanderson.org (S.A.); smeas@mdanderson.org (S.M.); vnsarli@mdanderson.org (V.N.S.); jrupshaw@mdanderson.org (J.R.U.); s2098055@online.houstonisd.org (M.M.) 3 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; sppatel@mdanderson.org 2 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; ychiang1@mdanderson.org (Y.-J.C.); jwargo@mdanderson.org (J.A.W.); jgershen@mdanderson.org (J.E.G.); mross@mdanderson.org (M.I.R.) |
| AuthorAffiliation_xml | – name: 1 Departments of Breast Surgical Oncology and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; saddanki@mdanderson.org (S.A.); smeas@mdanderson.org (S.M.); vnsarli@mdanderson.org (V.N.S.); jrupshaw@mdanderson.org (J.R.U.); s2098055@online.houstonisd.org (M.M.) – name: 2 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; ychiang1@mdanderson.org (Y.-J.C.); jwargo@mdanderson.org (J.A.W.); jgershen@mdanderson.org (J.E.G.); mross@mdanderson.org (M.I.R.) – name: 3 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; sppatel@mdanderson.org |
| Author_xml | – sequence: 1 givenname: Anthony orcidid: 0000-0003-4039-174X surname: Lucci fullname: Lucci, Anthony – sequence: 2 givenname: Sridevi surname: Addanki fullname: Addanki, Sridevi – sequence: 3 givenname: Yi-Ju surname: Chiang fullname: Chiang, Yi-Ju – sequence: 4 givenname: Salyna surname: Meas fullname: Meas, Salyna – sequence: 5 givenname: Vanessa N. surname: Sarli fullname: Sarli, Vanessa N. – sequence: 6 givenname: Joshua R. surname: Upshaw fullname: Upshaw, Joshua R. – sequence: 7 givenname: Mayank surname: Manchem fullname: Manchem, Mayank – sequence: 8 givenname: Sapna P. orcidid: 0000-0003-1339-1517 surname: Patel fullname: Patel, Sapna P. – sequence: 9 givenname: Jennifer A. surname: Wargo fullname: Wargo, Jennifer A. – sequence: 10 givenname: Jeffrey E. surname: Gershenwald fullname: Gershenwald, Jeffrey E. – sequence: 11 givenname: Merrick I. surname: Ross fullname: Ross, Merrick I. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37509290$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ksFvFCEUxompsXXt2Zsh8eJlWxiYYTiZZq06SY2N1jNhmDdTmhlYgdH0v5fJbk27UUiAwO_74PHeS3TkvAOEXlNyxpgk50Y7AyHSknJWMfIMnRREFOuqkvzo0foYncZ4R3JjjIpKvEDHTJREFpKcoOk6QITsg32PNzaYedTJugHfzJMPeAPjGHFmOp0g4mbSw3L4ARKYZL1bVN9g1NsI2Dp8nbXgUsS_bbrF35MeADdNg79kxPlJv0LPez1GON3PK_Tj4-XN5vP66uunZnNxtTa8lmltiIBamJpWtemNILygsiVt24EuCRSslIRzXvekM1LosutYrdtW6qrUtGCasBV6v_Pdzu0EnclvCnpU22AnHe6V11Y9PXH2Vg3-l6KECSHzf67Qu71D8D9niElNNpr8G9qBn6Mqas5JnUeZ0bcH6J2fg8vxLRQjnO4M99SgR1DW9T5fbBZTdSHKWhaiojRTZ_-gcu9gsianv7d5_4ngzeNI_4b4kOEMlDvABB9jgF4Zm_SSu-xsxxyxWopJHRRT1p0f6B6s_6f4A6x6zAw |
| CitedBy_id | crossref_primary_10_1016_j_critrevonc_2024_104483 crossref_primary_10_3389_fonc_2024_1416685 |
| Cites_doi | 10.1097/CMR.0000000000000168 10.1056/NEJMoa1709030 10.1001/jamaoncol.2020.2295 10.1007/978-3-319-40618-3 10.1158/1078-0432.CCR-06-1695 10.1158/1078-0432.CCR-19-2670 10.1056/NEJMoa1708539 10.1158/1078-0432.CCR-05-1769 10.1056/NEJMoa1003466 10.1373/clinchem.2013.213611 10.3390/ijms222212416 10.1016/j.ejca.2009.09.004 10.1038/s41523-021-00239-3 10.1200/JCO.2011.40.0887 10.1093/annonc/mdu207 10.1056/NEJMoa1412082 10.3322/caac.21388 10.1158/1078-0432.CCR-15-0321 10.1158/2159-8290.CD-17-0716 10.1200/PO.16.00009 10.1016/j.cell.2014.07.013 10.1056/NEJMoa1103782 10.3322/caac.21708 10.1200/JCO.2005.02.0958 10.1158/1078-0432.CCR-13-3122 10.1038/onc.2014.249 10.1126/scitranslmed.3007094 10.3322/caac.21409 10.1016/j.gde.2009.12.002 10.1016/S0140-6736(18)31559-9 10.1016/j.ejca.2004.10.016 10.1016/j.ebiom.2015.05.011 10.1016/j.jamcollsurg.2018.04.026 10.1056/NEJMoa2211437 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2023 MDPI AG 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2023 by the authors. 2023 |
| Copyright_xml | – notice: COPYRIGHT 2023 MDPI AG – notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2023 by the authors. 2023 |
| DBID | AAYXX CITATION NPM 3V. 7T5 7TO 7XB 8FE 8FH 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO GNUQQ GUQSH H94 HCIFZ LK8 M2O M7P MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM |
| DOI | 10.3390/cancers15143630 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Immunology Abstracts Oncogenes and Growth Factors Abstracts ProQuest Central (purchase pre-March 2016) ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Biological Science Collection ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Korea ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts ProQuest SciTech Premium Collection Biological Sciences Research Library ProQuest Biological Science Database (NC LIVE) Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central (New) ProQuest Biological Science Collection ProQuest Central Basic ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2072-6694 |
| ExternalDocumentID | PMC10377914 A758927611 37509290 10_3390_cancers15143630 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIH Melanoma SPORE Developmental Research Project grantid: P50-CA221703 – fundername: The Marvin M. Romsdahl MD PhD Endowed Professorship – fundername: the Clift Family Estate Foundation – fundername: the Simon and Linda Eyles Foundation – fundername: the Sam and Janna Moore family – fundername: the Kiefer family – fundername: philanthropic funds – fundername: Harry and Jane Pefanis – fundername: the Wintermann Foundation – fundername: The John Wayne Cancer Foundation |
| GroupedDBID | --- 53G 5VS 8FE 8FH 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ CCPQU CITATION DIK DWQXO E3Z EBD ESX GNUQQ GUQSH GX1 HCIFZ HYE IAO IHR ITC KQ8 LK8 M2O M48 M7P MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS NPM PMFND 3V. 7T5 7TO 7XB 8FK H94 MBDVC PKEHL PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c489t-c07e87c8168cfc704219b0bbdea50e235904448f0dc97a5dd38abb9a65a123a03 |
| IEDL.DBID | M48 |
| ISSN | 2072-6694 |
| IngestDate | Thu Aug 21 18:36:58 EDT 2025 Fri Sep 05 13:07:42 EDT 2025 Sun Jul 13 05:28:05 EDT 2025 Tue Jun 17 21:26:46 EDT 2025 Tue Jun 10 21:25:24 EDT 2025 Thu Apr 03 06:58:35 EDT 2025 Tue Jul 01 01:21:27 EDT 2025 Thu Apr 24 22:59:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 14 |
| Keywords | melanoma circulating tumor cell CTC radiologic surveillance biomarker liquid biopsy |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c489t-c07e87c8168cfc704219b0bbdea50e235904448f0dc97a5dd38abb9a65a123a03 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0003-1339-1517 0000-0003-4039-174X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers15143630 |
| PMID | 37509290 |
| PQID | 2843041914 |
| PQPubID | 2032421 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10377914 proquest_miscellaneous_2844082849 proquest_journals_2843041914 gale_infotracmisc_A758927611 gale_infotracacademiconefile_A758927611 pubmed_primary_37509290 crossref_citationtrail_10_3390_cancers15143630 crossref_primary_10_3390_cancers15143630 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20230715 |
| PublicationDateYYYYMMDD | 2023-07-15 |
| PublicationDate_xml | – month: 7 year: 2023 text: 20230715 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland – name: Basel |
| PublicationTitle | Cancers |
| PublicationTitleAlternate | Cancers (Basel) |
| PublicationYear | 2023 |
| Publisher | MDPI AG MDPI |
| Publisher_xml | – name: MDPI AG – name: MDPI |
| References | Gershenwald (ref_5) 2017; 67 Radovich (ref_30) 2020; 6 Rizos (ref_11) 2014; 20 Gagnon (ref_18) 2016; 22 Stark (ref_17) 2015; 2 Khoja (ref_16) 2015; 26 Long (ref_8) 2017; 377 Chaudhuri (ref_35) 2017; 7 Riethdorf (ref_36) 2007; 13 Hodi (ref_9) 2010; 363 Robert (ref_13) 2015; 372 Magbanua (ref_34) 2021; 7 Lucci (ref_23) 2020; 26 Aceto (ref_14) 2014; 158 Koyanagi (ref_29) 2005; 23 Schadendorf (ref_1) 2018; 392 Hall (ref_22) 2018; 227 Weber (ref_10) 2017; 377 Fusi (ref_19) 2009; 45 Chapman (ref_7) 2011; 364 Roesch (ref_12) 2014; 34 Chiu (ref_21) 2014; 60 Roland (ref_25) 2015; 25 Wong (ref_33) 2017; 1 Gandini (ref_2) 2005; 41 Siegel (ref_3) 2022; 72 Hoshimoto (ref_20) 2012; 30 Budd (ref_28) 2006; 12 Patel (ref_31) 2023; 388 Bettegowda (ref_32) 2014; 6 ref_27 ref_26 Maheswaran (ref_15) 2010; 20 Amin (ref_24) 2017; 67 ref_4 ref_6 |
| References_xml | – volume: 25 start-page: 335 year: 2015 ident: ref_25 article-title: Detection of circulating melanoma cells in the blood of melanoma patients: A preliminary study publication-title: Melanoma Res. doi: 10.1097/CMR.0000000000000168 – volume: 377 start-page: 1824 year: 2017 ident: ref_10 article-title: Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709030 – volume: 6 start-page: 1410 year: 2020 ident: ref_30 article-title: Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2020.2295 – ident: ref_6 doi: 10.1007/978-3-319-40618-3 – volume: 13 start-page: 920 year: 2007 ident: ref_36 article-title: Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-1695 – volume: 26 start-page: 1886 year: 2020 ident: ref_23 article-title: Circulating Tumor Cells and Early Relapse in Node-positive Melanoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-2670 – volume: 377 start-page: 1813 year: 2017 ident: ref_8 article-title: Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1708539 – volume: 12 start-page: 6403 year: 2006 ident: ref_28 article-title: Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-05-1769 – volume: 363 start-page: 711 year: 2010 ident: ref_9 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 60 start-page: 873 year: 2014 ident: ref_21 article-title: Genome-Wide Characterization of Circulating Tumor Cells Identifies Novel Prognostic Genomic Alterations in Systemic Melanoma Metastasis publication-title: Clin. Chem. doi: 10.1373/clinchem.2013.213611 – ident: ref_26 doi: 10.3390/ijms222212416 – volume: 45 start-page: 3189 year: 2009 ident: ref_19 article-title: Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study) publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2009.09.004 – volume: 7 start-page: 32 year: 2021 ident: ref_34 article-title: Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk publication-title: NPJ Breast Cancer doi: 10.1038/s41523-021-00239-3 – volume: 30 start-page: 3819 year: 2012 ident: ref_20 article-title: Association between Circulating Tumor Cells and Prognosis in Patients with Stage III Melanoma with Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.40.0887 – volume: 26 start-page: 33 year: 2015 ident: ref_16 article-title: Circulating tumour cells as tumour biomarkers in melanoma: Detection methods and clinical relevance publication-title: Ann. Oncol. doi: 10.1093/annonc/mdu207 – volume: 372 start-page: 320 year: 2015 ident: ref_13 article-title: Nivolumab in previously untreated melanoma without BRAF mutation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1412082 – volume: 67 start-page: 93 year: 2017 ident: ref_24 article-title: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21388 – volume: 22 start-page: 567 year: 2016 ident: ref_18 article-title: Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0321 – volume: 7 start-page: 1394 year: 2017 ident: ref_35 article-title: Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-17-0716 – volume: 1 start-page: 1 year: 2017 ident: ref_33 article-title: Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma publication-title: JCO Precis. Oncol. doi: 10.1200/PO.16.00009 – volume: 158 start-page: 1110 year: 2014 ident: ref_14 article-title: Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis publication-title: Cell doi: 10.1016/j.cell.2014.07.013 – volume: 364 start-page: 2507 year: 2011 ident: ref_7 article-title: Faculty Opinions recommendation of Improved survival with vemurafenib in melanoma with BRAF V600E mutation publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1103782 – volume: 72 start-page: 7 year: 2022 ident: ref_3 article-title: Cancer statistics, 2022 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21708 – volume: 23 start-page: 8057 year: 2005 ident: ref_29 article-title: Serial Monitoring of Circulating Melanoma Cells during Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2005.02.0958 – volume: 20 start-page: 1965 year: 2014 ident: ref_11 article-title: BRAF inhibitor resistance mechanisms in metastatic melanoma: Spectrum and clinical impact publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-3122 – volume: 34 start-page: 2951 year: 2014 ident: ref_12 article-title: Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma publication-title: Oncogene doi: 10.1038/onc.2014.249 – volume: 6 start-page: 224ra24 year: 2014 ident: ref_32 article-title: Detection of circulating tumor DNA in early- and late-stage human malignancies publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3007094 – ident: ref_4 – volume: 67 start-page: 472 year: 2017 ident: ref_5 article-title: Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21409 – ident: ref_27 – volume: 20 start-page: 96 year: 2010 ident: ref_15 article-title: Circulating tumor cells: A window into cancer biology and metastasis publication-title: Curr. Opin. Genet. Dev. doi: 10.1016/j.gde.2009.12.002 – volume: 392 start-page: 971 year: 2018 ident: ref_1 article-title: Melanoma publication-title: Lancet doi: 10.1016/S0140-6736(18)31559-9 – volume: 41 start-page: 45 year: 2005 ident: ref_2 article-title: Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2004.10.016 – volume: 2 start-page: 671 year: 2015 ident: ref_17 article-title: The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis publication-title: Ebiomedicine doi: 10.1016/j.ebiom.2015.05.011 – volume: 227 start-page: 116 year: 2018 ident: ref_22 article-title: Circulating Tumor Cells in Stage IV Melanoma Patients publication-title: J. Am. Coll. Surg. doi: 10.1016/j.jamcollsurg.2018.04.026 – volume: 388 start-page: 813 year: 2023 ident: ref_31 article-title: Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa2211437 |
| SSID | ssj0000331767 |
| Score | 2.3323276 |
| Snippet | Stage III melanoma includes nodal metastasis or in-transit disease. Five-year survival rates vary between 32% and 93%. The identification of high-risk patients... In this study, we investigated how frequently and how early circulating tumor cells (CTCs) were identified prior to the surveillance imaging detection of... Simple SummaryIn this study, we investigated how frequently and how early circulating tumor cells (CTCs) were identified prior to the surveillance imaging... |
| SourceID | pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 3630 |
| SubjectTerms | Antigens Biomarkers Biopsy Cancer Care and treatment Computed tomography CT imaging Decision making Diagnosis Diseases FDA approval Intervention Ipilimumab Lymphatic system Medical prognosis Medical research Medicine, Experimental Melanoma Metastases Metastasis MicroRNAs Patients PET imaging Relapse Risk groups Surveillance Tumor cells Tumors |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdGJyFeEN8EBjISEryE5ctx_IDQKJtWpFYV2qS9RfbZ3Sq1SWna_5-7fNFMgmefEyt3vg_n_Psx9jECo22qhZ9Yk_hJlijfSOl8YSMRRwDW1Oj601l6eZ38vBE3R2zW3YWhtsrOJ9aO2pZAZ-Sn6Eax8iY0sm-b3z6xRtHf1Y5CQ7fUCvZrDTH2gB2jSxbBiB1_P5_Nf_WnLkGM8TKVDcZPjPX-KdDH3VYhJQ4p9UIfhKf7TvogSg07KA9C0sUT9rjNJflZo_yn7MgVz9jDafu3_Dlbz-u7ReB4ueDj5RZqqq7ill_t1-WWj91qVXGUoaK_4pN1TVjEf7hd3Z5V0CzqldtUji8LPm8QWCtOR7cck9RbxyeTCZ-iSFGu9Qt2fXF-Nb70W3oFH5JM7XwIpMskEPEGLEDi7g2VCYyxTovARbFQhCWXLQILSmphbZxpY5ROhcZwp4P4JRsVZeFeMx7rVCqMcpApSGQEWrnUpPQME2itpce-dF81hxZ7nCgwVjnWIKSG_J4aPPa5n7BpYDf-LfqJ1JTThsRngm7vFeDKCNoqP8OKSEUyDUOPnQwkcSPBcLhTdN5u5Cr_a3Ye-9AP00xqTitcua9liLYb7dxjrxq76BcdU0YWKVxlNrCYXoDgvYcjxfKuhvmmG5wSX_zm_-t6yx5FmHjReXMoTthot927d5go7cz71vr_AFe0FPY priority: 102 providerName: ProQuest |
| Title | Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37509290 https://www.proquest.com/docview/2843041914 https://www.proquest.com/docview/2844082849 https://pubmed.ncbi.nlm.nih.gov/PMC10377914 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3da9swED-2Fkpfxr7ntgsaDLYXd_6UrIcxuqxdM0gJo4G8GUlWukBid3YC23-_O9nJktI-6yQb3Ul3J51-P4D3kdGq4Cr1k0InfpIl0tdCWD8tojSOjCm0Q9cfXvHLcfJjkk7-0wF1E9jcm9oRn9S4np_--f33Cy74z5RxYsr-ydD81E1Ivp_HmL_vu8siquPrYn23LcfoKh2jbBSIyOdcJi3Uz31jHMJBTL40or16y2Hd3ba3_NZuTeWWk7p4Ck-66JKdtebwDB7Z8jkcDLv78xewGLnXRsayasr6s9o48q7yhl2vFlXN-nY-bxjK0DFAwwYLR2HEvtmlK9gqqRdVz902ls1KNmoxWRtGh7kMw9YbywaDARuiSFkt1EsYX5xf9y_9jnDBN0kml74JhM2EISoOMzUC13ModaB1YVUa2ChOJaHLZdOgMFKotCjiTGktFU8VOkAVxK9gr6xK-wZYrLiQ6PdMJk0iIqOk5ZrTGDpQSgkPTtezmpsOjZxIMeY5ZiWkkfyORjz4uOlw2wJxPCz6gdSUk9HgmEZ1Lw3wzwjsKj_DHElGgoehByc7kri0zG7zWtH52jJz9OdxkBAsngfvNs3Uk8rVSlutnAwReaPle_C6tYvNT6_tyoNsx2I2AgT4vdtSzn454G960ynww0cPDnoMhxFGYXT4HKYnsLesV_YtRk1L3YP9r-dXo589ePx9Evbc2vgH7jUWig |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED-NTgJeJr7JGGAkELyE5dvxw4RGt6lha1WhTtpbsB13VGqT0rRC_HP8bdwlaWgnwduefXas3PnufL77HcBbTyuZRTK0g0wFdhAHwlacGzvMvND3tM5Uha7fH0S9y-DLVXi1A7_XtTCUVrnWiZWizgpNMfJDVKN48yY0sk_zHzZ1jaLX1XULDdm0VsiOKoixprDj3Pz6iVe48ig5QX6_87yz01G3ZzddBmwdxGJpa4ebmGvqP6HHmqMQu0I5SmVGho7x_FAQpFo8djItuAyzzI-lUkJGoUStLx0f170DuwEFUDqw-_l0MPzaRnkcH-1zxGtMId8XzqEmZi5KlxyViHKvN8zhTaOwYRW3MzY3TODZA9hrfFd2XAvbQ9gx-SO4229e5x_DbFjVMmnDijHrTha6ag2WX7PRalYsWNdMpyVDGgoylCyZVQ2S2IlZVulgOc2i3Lx5adgkZ8Ma8bVkFCpm6BRfG5YkCesjSV7M5BO4vJUf_RQ6eZGb58B8GXGBVlXHQgfc01KYSEW0hnKklNyCj-u_muoG65xabkxTvPMQG9IbbLDgQzthXsN8_Jv0PbEpJQWAa2rZ1DHgzghKKz3GG5jweOS6FhxsUeLB1dvDa0anjeIo079ibsGbdphmUjJcbopVRUNtwvFcWfCslot20z55gJ7AXcZbEtMSEJz49kg--V7BilPFKMcP7_9_X6_hXm_Uv0gvksH5C7jvodNHsW43PIDOcrEyL9FJW6pXzUlg8O22D98fEJtR9Q |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVqq4IN6YFlgkEFxM_F7voUIlaVRTEkWolXpz95USKbHTOBHiL_KrmPGLuBLcet7Z9cqz89zZbwh55ykpdCRCO9AysIM44LZkzNih9kLfU0rLEl1_NI5OL4Kvl-HlDvndvIXBsspGJ5aKWucKc-Q9UKMQeSMaWW9al0VMBsPPyxsbO0jhTWvTTkPUbRb0UQk3Vj_yODO_fkI4VxwlA-D9e88bnpz3T-2644CtgpivbeUwEzOFvSjUVDE40C6XjpTaiNAxnh9yhFeLp45WnIlQaz8WUnIRhQIsgHB8WPce2WNg9SEQ3PtyMp58bzM-jg-2OmIVvpDvc6enkLGrwkWnJcI67C3TeNtAbFnIbvXmljkcPiQPaj-WHlcH7xHZMdljsj-qb-qfkMWkfNekDM2ntD9bqbJNWHZNzzeLfEX7Zj4vKNBgwqGgyaJslkQHZl2WhmU4C-v0loWhs4xOKvTXgmLamIKDfG1okiR0BCRZvhBPycWd_OhnZDfLM_OCUF9EjIOFVTFXAfOU4CaSEa4hHSEEs8in5q-mqsY9x_Yb8xTiH2RDeosNFvnYTlhWkB__Jv2AbEpRGcCaStRvGmBnCKuVHkM0xj0Wua5FDjuUIMSqO9wwOq2VSJH-PfIWedsO40wsjMtMvilpsGU4yJhFnlfnot20j96gx2GXcefEtAQILd4dyWY_SohxfD3K4MMv_7-vN2QfhDD9lozPDsh9D_w_THu74SHZXa825hX4a2v5uhYESq7uWvb-AN2vVjk |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Presence+of+Circulating+Tumor+Cells+Predates+Imaging+Detection+of+Relapse+in+Patients+with+Stage+III+Melanoma&rft.jtitle=Cancers&rft.au=Lucci%2C+Anthony&rft.au=Addanki%2C+Sridevi&rft.au=Chiang%2C+Yi-Ju&rft.au=Meas%2C+Salyna&rft.date=2023-07-15&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=15&rft.issue=14&rft_id=info:doi/10.3390%2Fcancers15143630&rft_id=info%3Apmid%2F37509290&rft.externalDocID=37509290 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon |